Sat, Dec 20, 2014, 10:03 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Idera Pharmaceuticals, Inc. Message Board

  • techtrader79 techtrader79 Feb 6, 2014 9:39 PM Flag

    Idera medical device and partner for Lymphoma???

    Someone posted a clip from an SEC filing to this effect, but I can't locate the post to follow up on it. Can some follow up with details or a pointer. This peaked my interest. Thanks.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • To all on this thread - WOW! This is why I love IDRA, and I truly appreciate the YMB, and, more specifically, folks like you all who add such factual and insightful perspectives. Great stuff. Truly, thank you!!! GLTA

    • I found it!

      Diagnovus Launches First Commercial Gene Expression Assay for Patients With Diffuse Large B-Cell Lymphoma

      February 20, 2013
      SHARE

      TOOLS
      Print
      NASHVILLE, Tenn.--Diagnovus, LLC, a molecular diagnostic company focused on underserved, aggressive and lesser-known diseases, today announced the launch of ENGAUGETM-cancer-DLBCL, the first commercial gene expression assay that can aid physicians in better risk stratification and treatment of patients with diffuse large B-cell lymphoma (DLBCL).

      DLBCL is an aggressive tumor that can arise in virtually any part of the body. It is the most common sub-type of non-Hodgkin lymphoma, with an incidence of 7-8 cases per 100,000 people per year. Physicians currently assess a patient's DLBCL risk of disease progression and outcome by using the International Prognostic Index (IPI), but more accurate classification of patients based on the underlying tumor biology is needed to allow physicians and patients to make more informed treatment decisions.

      "ENGAUGETM-cancer-DLBCL, which combines a patient's IPI score and the results of the gene expression assay, can more accurately predict outcomes for patients than IPI alone in order to optimize treatment choices for patients," said Dr. Ron Levy, leader of the Lymphoma Program at Stanford University School of Medicine. "Traditional stratification schemes based on clinical characteristics such as the IPI have provided prognostic guidance in the management of patients with DLBCL. Despite the ease of use, IPI does not fully capture disease heterogeneity, and it is common to have two patients with identical IPI risk scores have very different outcomes."

      Sentiment: Strong Buy

      • 1 Reply to rtellis444
      • Part 2

        Dr. Izidore Lossos, University of Miami head of Lymphoma, said, "Application of better prognostic models at diagnosis will change the treatment of DLBCL patients, leading to more effective care. Knowledge of molecular prognostic markers may identify cellular mechanisms leading to the recognition of specific molecular targets for new therapeutic approaches."

        According to James Stover, Ph.D., vice president and co-founder of Diagnovus, the company is committed to bringing personalized medicine to patients afflicted with these aggressive, underserved diseases by developing assays that assist physicians in achieving better outcomes for their patients. The ENGAUGETM-cancer-DLBCL assay is the first of a comprehensive line of molecular diagnostic tests for less frequent diseases.

        "Using well-studied genes incorporated into a multiplexed panel, ENGAUGETM-cancer-DLBCL has been developed from more than 10 years of research and exceeds the standard clinical characteristics that clinicians have used for prognosis for the last three decades," Dr. Stover said. "Even more important is the fact that we can perform this assay in a reproducible and accurate manner using routinely available formalin-fixed, paraffin-embedded (FFPE) diagnostic biopsy tissue, unlike other genome-based assays that require special handling, such as snap freezing in liquid nitrogen."

        Subscribe at FierceMedicalDevices

        Sentiment: Strong Buy

    • Sure. It's in the Prospectus filed by Idera called a Form 424B5.

      • 1 Reply to rtellis444
      • Thanks. Interesting. "In parallel with our anticipated Phase 1/2 clinical trials in patients with genetically defined B-cell lymphoma, we are seeking to collaborate with an experienced medical device company to develop and commercialize a companion diagnostic device. We currently anticipate entering into our first companion diagnostic collaboration during the first half of 2014."

        So what type of diagnostic "device" would one create for Lymphoma? I can understand a diagnostic blood test or assay, but device implies some type of scanner or similar. And partner? Who? Would that same partner also be interested in IMO-8400 as well? Sounds like these guys have something in the works, but what? I wonder if the Baker Bros got a bit more info in exchange for their large investment?

 
IDRA
4.12-0.0500(-1.20%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.